Chinese General Practice ›› 2023, Vol. 26 ›› Issue (22): 2763-2770.DOI: 10.12114/j.issn.1007-9572.2023.0131
• Original Research·Foucus on Health Status in Middle-aged and Older Populations • Previous Articles Next Articles
Received:
2023-03-13
Revised:
2023-04-13
Published:
2023-08-05
Online:
2023-05-04
Contact:
FU Xiaoli
通讯作者:
付晓丽
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0131
组别 | 例数 | 感知严重性维度得分 | 感知易感性维度得分 | 感知利益维度得分 | 感知障碍维度得分 | 医生信任度维度得分 | 疫苗开发者信任度维度得分 |
---|---|---|---|---|---|---|---|
接种第一剂新冠疫苗 | 1 278 | 10.52±3.27 | 4.61±2.00 | 12.16±2.47 | 7.97±3.40 | 35.87±5.36 | 20.43±3.44 |
未接种第一剂新冠疫苗 | 45 | 9.73±2.87 | 4.78±1.95 | 11.24±2.80 | 8.60±3.25 | 34.38±5.93 | 19.89±3.32 |
t值 | 1.596 | -0.564 | 2.420 | -1.226 | 1.824 | 1.033 | |
P值 | 0.111 | 0.573 | 0.016 | 0.220 | 0.068 | 0.302 | |
完成新冠疫苗全程接种 | 1 214 | 10.54±3.27 | 4.61±2.01 | 12.18±2.46 | 7.95±3.40 | 35.93±5.33 | 20.46±3.43 |
未完成新冠疫苗全程接种 | 109 | 9.95±3.05 | 4.63±1.88 | 11.54±2.71 | 8.43±3.27 | 34.60±5.85 | 19.83±3.47 |
t值 | 1.809 | -0.113 | 2.562 | -1.417 | 2.474 | 1.822 | |
P值 | 0.071 | 0.905 | 0.011 | 0.157 | 0.014 | 0.069 | |
接种新冠疫苗加强剂 | 1 054 | 10.63±3.26 | 4.59±2.01 | 12.26±2.43 | 7.79±3.37 | 36.19±5.30 | 20.67±3.35 |
未接种新冠疫苗加强剂 | 269 | 9.79±3.19 | 4.69±1.95 | 11.59±2.65 | 8.77±3.39 | 34.36±5.51 | 19.38±3.56 |
t值 | 2.965 | -0.693 | 3.964 | -4.226 | 5.011 | 5.551 | |
P值 | 0.003 | 0.489 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of scores of the COVID-19 Vaccine Perception Scale,Trust in Doctors and Vaccine Developers Questionnaire among the elderly with different COVID-19 vaccination status
组别 | 例数 | 感知严重性维度得分 | 感知易感性维度得分 | 感知利益维度得分 | 感知障碍维度得分 | 医生信任度维度得分 | 疫苗开发者信任度维度得分 |
---|---|---|---|---|---|---|---|
接种第一剂新冠疫苗 | 1 278 | 10.52±3.27 | 4.61±2.00 | 12.16±2.47 | 7.97±3.40 | 35.87±5.36 | 20.43±3.44 |
未接种第一剂新冠疫苗 | 45 | 9.73±2.87 | 4.78±1.95 | 11.24±2.80 | 8.60±3.25 | 34.38±5.93 | 19.89±3.32 |
t值 | 1.596 | -0.564 | 2.420 | -1.226 | 1.824 | 1.033 | |
P值 | 0.111 | 0.573 | 0.016 | 0.220 | 0.068 | 0.302 | |
完成新冠疫苗全程接种 | 1 214 | 10.54±3.27 | 4.61±2.01 | 12.18±2.46 | 7.95±3.40 | 35.93±5.33 | 20.46±3.43 |
未完成新冠疫苗全程接种 | 109 | 9.95±3.05 | 4.63±1.88 | 11.54±2.71 | 8.43±3.27 | 34.60±5.85 | 19.83±3.47 |
t值 | 1.809 | -0.113 | 2.562 | -1.417 | 2.474 | 1.822 | |
P值 | 0.071 | 0.905 | 0.011 | 0.157 | 0.014 | 0.069 | |
接种新冠疫苗加强剂 | 1 054 | 10.63±3.26 | 4.59±2.01 | 12.26±2.43 | 7.79±3.37 | 36.19±5.30 | 20.67±3.35 |
未接种新冠疫苗加强剂 | 269 | 9.79±3.19 | 4.69±1.95 | 11.59±2.65 | 8.77±3.39 | 34.36±5.51 | 19.38±3.56 |
t值 | 2.965 | -0.693 | 3.964 | -4.226 | 5.011 | 5.551 | |
P值 | 0.003 | 0.489 | <0.001 | <0.001 | <0.001 | <0.001 |
项目 | 例数 | 接种第一剂新冠疫苗 | 完成新冠疫苗全程接种 | 接种新冠疫苗加强剂 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
例数 | χ2值 | P值 | 例数 | χ2值 | P值 | 例数 | χ2值 | P值 | ||
年龄(岁) | 16.302 | 0.001 | 25.735 | <0.001 | 11.595 | 0.009 | ||||
60~64 | 495 | 485(97.98) | 466(94.14) | 412(83.23) | ||||||
65~69 | 399 | 388(97.24) | 371(92.98) | 317(79.45) | ||||||
70~74 | 263 | 253(96.20) | 241(91.63) | 207(78.71) | ||||||
≥75 | 166 | 152(91.57) | 136(81.93) | 118(71.08) | ||||||
性别 | 3.138 | 0.077 | 3.166 | 0.075 | 2.486 | 0.115 | ||||
男 | 642 | 626(97.51) | 598(93.15) | 523(81.46) | ||||||
女 | 681 | 652(95.74) | 616(90.46) | 531(77.97) | ||||||
婚姻状况 | 0.692 | 0.405 | 0.352 | 0.553 | 0.104 | 0.747 | ||||
在婚 | 1 259 | 1 215(96.51) | 1 154(91.66) | 1 002(79.59) | ||||||
其他(未婚、离异、丧偶) | 64 | 63(98.44) | 60(93.75) | 52(81.25) | ||||||
文化程度 | 0.332 | 0.565 | 1.228 | 0.268 | 0.170 | 0.680 | ||||
初中及以下 | 1 011 | 975(96.44) | 923(91.30) | 808(79.92) | ||||||
高中/中专及以上 | 312 | 303(97.12) | 291(93.27) | 246(78.85) | ||||||
来自地区 | 6.223 | 0.101 | 9.219 | 0.027 | 41.390 | <0.001 | ||||
东部地区 | 621 | 603(97.10) | 559(90.02) | 449(72.30) | ||||||
中部地区 | 452 | 430(95.13) | 418(92.48) | 384(84.96) | ||||||
西部地区 | 40 | 38(95.00) | 35(87.50) | 33(82.50) | ||||||
东北地区 | 210 | 207(98.57) | 202(96.19) | 188(89.52) | ||||||
居住地 | 1.674 | 0.196 | 1.829 | 0.176 | 1.531 | 0.216 | ||||
社区 | 713 | 693(97.19) | 661(92.71) | 559(78.40) | ||||||
村庄 | 610 | 585(95.90) | 553(90.66) | 495(81.15) | ||||||
保持规律的体育锻炼 | 3.379 | 0.066 | 9.152 | 0.002 | 3.933 | 0.047 | ||||
是 | 764 | 744(97.38) | 716(93.72) | 623(81.54) | ||||||
否 | 559 | 534(95.53) | 498(89.09) | 431(77.10) | ||||||
患有慢性病 | 8.181 | 0.004 | 9.773 | 0.002 | 18.100 | <0.001 | ||||
是 | 496 | 470(94.76) | 440(88.71) | 365(73.59) | ||||||
否 | 827 | 808(97.70) | 774(93.59) | 689(83.31) |
Table 2 Comparison of COVID-19 vaccination status among the elderly with different characteristics
项目 | 例数 | 接种第一剂新冠疫苗 | 完成新冠疫苗全程接种 | 接种新冠疫苗加强剂 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
例数 | χ2值 | P值 | 例数 | χ2值 | P值 | 例数 | χ2值 | P值 | ||
年龄(岁) | 16.302 | 0.001 | 25.735 | <0.001 | 11.595 | 0.009 | ||||
60~64 | 495 | 485(97.98) | 466(94.14) | 412(83.23) | ||||||
65~69 | 399 | 388(97.24) | 371(92.98) | 317(79.45) | ||||||
70~74 | 263 | 253(96.20) | 241(91.63) | 207(78.71) | ||||||
≥75 | 166 | 152(91.57) | 136(81.93) | 118(71.08) | ||||||
性别 | 3.138 | 0.077 | 3.166 | 0.075 | 2.486 | 0.115 | ||||
男 | 642 | 626(97.51) | 598(93.15) | 523(81.46) | ||||||
女 | 681 | 652(95.74) | 616(90.46) | 531(77.97) | ||||||
婚姻状况 | 0.692 | 0.405 | 0.352 | 0.553 | 0.104 | 0.747 | ||||
在婚 | 1 259 | 1 215(96.51) | 1 154(91.66) | 1 002(79.59) | ||||||
其他(未婚、离异、丧偶) | 64 | 63(98.44) | 60(93.75) | 52(81.25) | ||||||
文化程度 | 0.332 | 0.565 | 1.228 | 0.268 | 0.170 | 0.680 | ||||
初中及以下 | 1 011 | 975(96.44) | 923(91.30) | 808(79.92) | ||||||
高中/中专及以上 | 312 | 303(97.12) | 291(93.27) | 246(78.85) | ||||||
来自地区 | 6.223 | 0.101 | 9.219 | 0.027 | 41.390 | <0.001 | ||||
东部地区 | 621 | 603(97.10) | 559(90.02) | 449(72.30) | ||||||
中部地区 | 452 | 430(95.13) | 418(92.48) | 384(84.96) | ||||||
西部地区 | 40 | 38(95.00) | 35(87.50) | 33(82.50) | ||||||
东北地区 | 210 | 207(98.57) | 202(96.19) | 188(89.52) | ||||||
居住地 | 1.674 | 0.196 | 1.829 | 0.176 | 1.531 | 0.216 | ||||
社区 | 713 | 693(97.19) | 661(92.71) | 559(78.40) | ||||||
村庄 | 610 | 585(95.90) | 553(90.66) | 495(81.15) | ||||||
保持规律的体育锻炼 | 3.379 | 0.066 | 9.152 | 0.002 | 3.933 | 0.047 | ||||
是 | 764 | 744(97.38) | 716(93.72) | 623(81.54) | ||||||
否 | 559 | 534(95.53) | 498(89.09) | 431(77.10) | ||||||
患有慢性病 | 8.181 | 0.004 | 9.773 | 0.002 | 18.100 | <0.001 | ||||
是 | 496 | 470(94.76) | 440(88.71) | 365(73.59) | ||||||
否 | 827 | 808(97.70) | 774(93.59) | 689(83.31) |
自变量 | 接种第一剂新冠疫苗 | 完成新冠疫苗全程接种 | 接种新冠疫苗加强剂 | ||||||
---|---|---|---|---|---|---|---|---|---|
b | OR(95%CI) | P值 | b | OR(95%CI) | P值 | b | OR(95%CI) | P值 | |
年龄(岁,以60~64为参照) | |||||||||
65~69 | -0.25 | 0.78(0.32,1.85) | 0.568 | -0.18 | 0.84(0.49,1.45) | 0.526 | -0.26 | 0.77(0.54,1.10) | 0.150 |
70~74 | -0.57 | 0.57(0.23,1.39) | 0.214 | -0.35 | 0.70(0.39,1.26) | 0.237 | -0.30 | 0.74(0.50,1.10) | 0.139 |
≥75 | -1.33 | 0.27(0.11,0.62) | 0.002 | -1.09 | 0.34(0.19,0.59) | <0.001 | -0.59 | 0.55(0.36,0.86) | 0.008 |
来自地区(以中部地区为参照) | |||||||||
东部地区 | — | — | — | -0.26 | 0.77(0.49,1.21) | 0.258 | -0.76 | 0.47(0.34,0.64) | <0.001 |
西部地区 | — | — | — | -0.44 | 0.64(0.23,1.82) | 0.407 | -0.18 | 0.83(0.34,2.01) | 0.682 |
东北地区 | — | — | — | 0.44 | 1.56(0.68,3.55) | 0.291 | 0.02 | 0.98(0.57,1.71) | 0.955 |
保持规律的体育锻炼(以是为参照) | |||||||||
否 | — | — | — | -0.45 | 0.64(0.42,0.96) | 0.031 | -0.15 | 0.86(0.65,1.14) | 0.296 |
患有慢性病(以是为参照) | |||||||||
否 | 0.73 | 2.07(1.12,3.84) | 0.021 | 0.46 | 1.59(1.05,2.40) | 0.029 | 0.43 | 1.54(1.15,2.06) | 0.003 |
感知严重性维度得分(z-标准化处理后实际值进入) | — | — | — | — | — | — | 0.05 | 1.06(1.00,1.11) | 0.033 |
感知利益维度得分(z-标准化处理后实际值进入) | 0.33 | 1.39(1.07,1.79) | 0.013 | 0.06 | 1.06(0.97,1.15) | 0.192 | 0.03 | 1.03(0.96,1.10) | 0.461 |
感知障碍维度得分(z-标准化处理后实际值进入) | — | — | — | — | — | — | -0.02 | 0.98(0.93,1.05) | 0.620 |
医生信任度维度得分(z-标准化处理后实际值进入) | — | — | — | 0.03 | 1.03(0.98,1.07) | 0.233 | 0.02 | 1.02(0.97,1.07) | 0.392 |
疫苗开发者信任度维度得分(z-标准化处理后实际值进入) | — | — | — | — | — | — | 0.06 | 1.06(0.98,1.14) | 0.123 |
Table 3 Binary Logistic regression analysis of influencing factors of the first dose of COVID-19 vaccine,full course of COVID-19 vaccination and booster dose of COVID-19 vaccine among the elderly
自变量 | 接种第一剂新冠疫苗 | 完成新冠疫苗全程接种 | 接种新冠疫苗加强剂 | ||||||
---|---|---|---|---|---|---|---|---|---|
b | OR(95%CI) | P值 | b | OR(95%CI) | P值 | b | OR(95%CI) | P值 | |
年龄(岁,以60~64为参照) | |||||||||
65~69 | -0.25 | 0.78(0.32,1.85) | 0.568 | -0.18 | 0.84(0.49,1.45) | 0.526 | -0.26 | 0.77(0.54,1.10) | 0.150 |
70~74 | -0.57 | 0.57(0.23,1.39) | 0.214 | -0.35 | 0.70(0.39,1.26) | 0.237 | -0.30 | 0.74(0.50,1.10) | 0.139 |
≥75 | -1.33 | 0.27(0.11,0.62) | 0.002 | -1.09 | 0.34(0.19,0.59) | <0.001 | -0.59 | 0.55(0.36,0.86) | 0.008 |
来自地区(以中部地区为参照) | |||||||||
东部地区 | — | — | — | -0.26 | 0.77(0.49,1.21) | 0.258 | -0.76 | 0.47(0.34,0.64) | <0.001 |
西部地区 | — | — | — | -0.44 | 0.64(0.23,1.82) | 0.407 | -0.18 | 0.83(0.34,2.01) | 0.682 |
东北地区 | — | — | — | 0.44 | 1.56(0.68,3.55) | 0.291 | 0.02 | 0.98(0.57,1.71) | 0.955 |
保持规律的体育锻炼(以是为参照) | |||||||||
否 | — | — | — | -0.45 | 0.64(0.42,0.96) | 0.031 | -0.15 | 0.86(0.65,1.14) | 0.296 |
患有慢性病(以是为参照) | |||||||||
否 | 0.73 | 2.07(1.12,3.84) | 0.021 | 0.46 | 1.59(1.05,2.40) | 0.029 | 0.43 | 1.54(1.15,2.06) | 0.003 |
感知严重性维度得分(z-标准化处理后实际值进入) | — | — | — | — | — | — | 0.05 | 1.06(1.00,1.11) | 0.033 |
感知利益维度得分(z-标准化处理后实际值进入) | 0.33 | 1.39(1.07,1.79) | 0.013 | 0.06 | 1.06(0.97,1.15) | 0.192 | 0.03 | 1.03(0.96,1.10) | 0.461 |
感知障碍维度得分(z-标准化处理后实际值进入) | — | — | — | — | — | — | -0.02 | 0.98(0.93,1.05) | 0.620 |
医生信任度维度得分(z-标准化处理后实际值进入) | — | — | — | 0.03 | 1.03(0.98,1.07) | 0.233 | 0.02 | 1.02(0.97,1.07) | 0.392 |
疫苗开发者信任度维度得分(z-标准化处理后实际值进入) | — | — | — | — | — | — | 0.06 | 1.06(0.98,1.14) | 0.123 |
Figure 1 Subgroup analysis of influencing factors of the booster dose of COVID-19 vaccine among the elderly based on the prevalence of chronic diseases
[1] |
|
[2] |
王国文,史秀欣,成海燕,等. 老年人新冠肺炎疫情常态化防控知信行调查[J]. 预防医学论坛,2022,28(11):801-805. DOI:10.16406/j.pmt.issn.1672-9153.2022.11.01.
|
[3] |
|
[4] |
COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age,time,and geography during the pre-vaccine era:a systematic analysis[J]. Lancet,2022,399(10334):1469-1488. DOI:10.1016/S0140-6736(21)02867-1.
|
[5] |
中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J]. 中华流行病学杂志,2020,41(2):145-151. DOI:10.3760/cma.j.issn.0254-6450.2020.02.003.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
国家卫生健康委员会. 国务院联防联控机制2022年11月29日新闻发布会文字实录[EB/OL].(2022-11-29)[2022-12-11].
|
[11] |
国家卫生健康委员会. 关于印发加强老年人新冠病毒疫苗接种工作方案的通知[A/OL]. (2022-11-29)[2022-12-11].
|
[12] |
国家统计局. 东西中部和东北地区划分方法[EB/OL]. (2011-06-13)[2023-04-09].
|
[13] |
国家卫生健康委员会. 国务院联防联控机制2022年5月6日新闻发布会文字实录[EB/OL].(2022-05-06)[2023-04-09].
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
Our World in Data. Coronavirus(COVID-19)vaccinations[EB/OL]. (2022-12-11)[2022-12-13].
|
[20] |
|
[21] |
|
[22] |
|
[23] |
中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版)[J]. 中华临床感染病杂志,2021,14(2):89-90. DOI:10.3760/cma.j.issn.1674-2397.2021.02.002.
|
[24] |
石春雷,宋晓哲,常桂秋,等. 徐州市某区冠心病患者流感疫苗接种情况及影响因素分析[J]. 中国公共卫生,2020,36(11):1628-1632. DOI:10.11847/zgggws1129035.
|
[25] |
|
[26] |
胡智聪. 老年人COVID-19疫苗加强剂接种意愿影响因素研究[J]. 卫生软科学,2022,36(11):91-96. DOI:10.3969/j.issn.1003-2800.2022.11.020.
|
[27] |
|
[28] |
|
[29] |
王述寒,田庆丰,张涵,等. 老年人综合能力现状及其与慢性病的相关性研究[J]. 中国全科医学,2021,24(36):4569-4573,4586. DOI:10.12114/j.issn.1007-9572.2021.02.063.
|
[30] |
|
[1] | YU Na, BAI Xiaoling, PANG Jin, NIU Yutian, HU Qing, WANG Yuanfang, YANG Rongze. The Experience of Inhaled COVID-19 Vaccination among First-line Medical Staff in Epidemic Prevention Aged≥18 Years in Guiyang City: a Qualitative Study [J]. Chinese General Practice, 2023, 26(36): 4575-4580. |
[2] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[3] | ZHANG Qian, LI Shu, LI Pengmei. Interpretation of the 2023 AGS Beers Criteria: Potentially Inappropriate Medication Use in Older Adults [J]. Chinese General Practice, 2023, 26(35): 4372-4381. |
[4] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[5] | ZHONG Pingping, NAN Yayun, PENG Linlin, ZHOU Yuting, CHEN Qiong. A Bibliometrics Analysis of Polypharmacy in the Elderly from 2003 to 2022 [J]. Chinese General Practice, 2023, 26(35): 4404-4411. |
[6] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[7] | XU Man, AN Zhuoling, ZHANG Yuhui, MA Zhuo. Current Situation of Potentially Inappropriate Medication in Older Cancer Patients and Strategies to Address It [J]. Chinese General Practice, 2023, 26(35): 4382-4387. |
[8] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[9] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[10] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[11] | GU Hanxin, LIU Yang, LIU Yuanli. Falls Prevention Intervention for Community-dwelling Older Adults from the Perspective of Policy Tools: an International Comparative Study [J]. Chinese General Practice, 2023, 26(34): 4231-4238. |
[12] | FENG Xiaoyu, LI Wanling, LYU Siman, NI Cuiping, WANG Haocheng, LIU Yu. International Research Status and Hot Spot Analysis of InterRAI HC Based on Bibliometrics [J]. Chinese General Practice, 2023, 26(34): 4351-4358. |
[13] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[14] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[15] | XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||